APOLLO ENDOSURGERY INC (APEN)
US03767D1081 - Common Stock
We assign a fundamental rating of 1 out of 10 to APEN. APEN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APEN have multiple concerns. APEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year APEN has reported negative net income.
APEN had a negative operating cash flow in the past year.
APEN had negative earnings in each of the past 5 years.
APEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
APEN has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APEN has a Gross Margin (55.20%) which is comparable to the rest of the industry.
APEN's Gross Margin has declined in the last couple of years.
APEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
APEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APEN has been increased compared to 1 year ago.
Compared to 5 years ago, APEN has more shares outstanding
Compared to 1 year ago, APEN has a worse debt to assets ratio.
2.2 Solvency
APEN has an Altman-Z score of -0.16. This is a bad value and indicates that APEN is not financially healthy and even has some risk of bankruptcy.
APEN has a Altman-Z score of -0.16. This is in the lower half of the industry: APEN underperforms 60.56% of its industry peers.
APEN has a Debt/Equity ratio of 1.04. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of APEN (1.04) is worse than 79.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.16 |
ROIC/WACCN/A
WACC10.2%
2.3 Liquidity
APEN has a Current Ratio of 2.35. This indicates that APEN is financially healthy and has no problem in meeting its short term obligations.
APEN's Current ratio of 2.35 is on the low side compared to the rest of the industry. APEN is outperformed by 66.20% of its industry peers.
APEN has a Quick Ratio of 1.89. This is a normal value and indicates that APEN is financially healthy and should not expect problems in meeting its short term obligations.
APEN has a worse Quick ratio (1.89) than 60.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The earnings per share for APEN have decreased by -9.99% in the last year.
APEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.01%.
Measured over the past years, APEN shows a small growth in Revenue. The Revenue has been growing by 3.63% on average per year.
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.21%
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y3.63%
Sales Q2Q%31.8%
3.2 Future
APEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.79% yearly.
The Revenue is expected to grow by 33.84% on average over the next years. This is a very strong growth
EPS Next Y13.1%
EPS Next 2Y11.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.29%
Revenue Next 2Y20.22%
Revenue Next 3Y33.84%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
APEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.79%
EPS Next 3YN/A
5. Dividend
5.1 Amount
APEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APOLLO ENDOSURGERY INC
NASDAQ:APEN (4/3/2023, 8:15:00 PM)
After market: 9.99 -0.01 (-0.1%)10
+0.08 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap475.49M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y